Through the Rights Issue, Cantargia receives approximately SEK 75 million before issue costs. In accordance with the terms and conditions of the loan agreement that the Company entered into with Fenja Capital II A/S in connection with the Rights Issue, the board of directors in the company has also, based on the authorization granted by the annual general meeting on 21 May 2026, resolved on a directed issue of 8,719,948 warrants series 2026/2031 to Fenja Capital.

“With the completion of this transaction, Cantargia has secured the capital required to execute our development plan and deliver on our strategic priorities. I would like to thank our participating shareholders for their continued support and welcome Fenja Capital as a financing partner. This strengthens our financial position and provides the flexibility to advance our clinical programs while continuing to build long-term value for patients and shareholders”, says Hilde Steineger, CEO of Cantargia.